Glaukos Corp

GKOS

Equity

ISIN null / Valor 28262610

New York Stock Exchange, Inc (2025-11-20)

USD 95.20-1.34%

Glaukos Corp
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Glaukos Corp, founded in 1998, is an ophthalmic medical technology and pharmaceutical company that specializes in developing and commercializing innovative therapies for glaucoma, corneal disorders, and retinal diseases. The company is known for pioneering Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to traditional glaucoma treatments, with a portfolio of technologically distinct platforms aimed at advancing the standard of care in ophthalmology. Glaukos completed an initial public offering in 2015 and is listed on the New York Stock Exchange under the ticker symbol "GKOS". With global headquarters in Aliso Viejo, California, and additional locations in several countries, Glaukos is dedicated to providing better treatment options for patients worldwide.

Summarized from source with an LLMView SourceSector: Healthcare

Q4 2024 Sales and Margins

For Q4 2024, Glaukos Corp reported record net sales of $105.5 million—a 28% increase year-over-year—with glaucoma net sales achieving $84.1 million, a 39% jump. Gross margins stood at approximately 73% (non-GAAP at 82%), marking solid performance even as operating expenses changed.

Expense and Operating Performance

During Q4 2024, SG&A expenses increased by 9% to $69.0 million, and R&D expenses slightly decreased to $36.5 million. Despite these changes, loss from operations and net loss figures improved compared to Q4 2023, with non-GAAP operating results showing marked improvement.

Full Year 2024 Overview

For the full year 2024, Glaukos Corp achieved net sales of $383.5 million, a 22% increase compared to 2023. Although the gross margins were slightly down, both GAAP and non-GAAP loss from operations improved, further highlighting the company's ability to manage expenses and drive revenue growth.

2025 Revenue Guidance

Looking ahead, Glaukos Corp has set its 2025 net sales guidance in the range of $475 million to $485 million, reflecting confidence in its continued growth and execution of its commercial and development strategies.

Summarized from source with an LLMView Source

Key figures

-32.7%1Y

94.8%3Y

48.1%5Y

Performance

52.5%1Y

44.2%3Y

48.5%5Y

Volatility